{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 15,
  "pageCount": 58,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "agenda",
  "function": "front_matter",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": [
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/15",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.52,
        "w": 0.61,
        "x": 0.038,
        "y": 0.215
      },
      "kind": "list",
      "text": "Context of clinical trial development in China\nFuture strategic trends of clinical trial development in China\nDevelopment of More Innovative and Differentiated Therapies\nIncreasing Focus of More Commercially Attractive Development Areas\nAdoption of Smarter Clinical Trial Tools\nA Two-way Pursuit: Globalization of Chinese Biopharma & Evolution of MNC China R&D strategy\nNext step questions\nResources and references\nAbout the authors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58998647-8006-45d4-8b8e-de63d1f36637",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.085,
        "x": 0.038,
        "y": 0.145
      },
      "kind": "title",
      "text": "Agenda",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e643a91b-670f-450e-be28-5fd52f297507",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 12,
      "beatId": "b805e1f5-4eeb-45d7-a58b-7531d46e8580",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f",
      "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.",
      "position": 0,
      "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}